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Hypoxia and inflammation have been associated with a number of patho-
logical conditions, in particular inflammatory diseases. While hypoxia is
mainly associated with the activation of hypoxia-inducible factors (HIFs),
inflammation activates the family of transcription factor called nuclear fac-
tor-kappa B (NF-jB). An extensive crosstalk between these two main
molecular players involved in hypoxia and inflammation has been demon-
strated. This crosstalk includes common activating stimuli, shared regula-
tors and targets. In this review, we discuss the current understanding of the
role of NF-jB and HIF in the context of the immune response. We review
the crosstalk between HIF and NF-jB in the control of the immune
response in different immune cell types including macrophages, neutrophils
and B and T cells. Furthermore the importance of the molecular crosstalk
between HIFs and NF-jB for a variety of medical conditions will be dis-
cussed.
Introduction
Nuclear factor-kappa B (NF-jB) is considered the
main pro-inflammatory family of transcription factors
involved in several relevant medical pathologies, such
as rheumatoid arthritis and cancer [1–3]. It was first
found by Ranjan Sen and David Baltimore in 1986 in
the context of the expression of a gene encoding
immunoglobulin-j light chain in B lymphocytes [4].
Since those findings, numerous reports have demon-
strated the involvement of several NF-jB subunits and
their mechanisms in the context of gene expression,
signalling pathways, and/or human diseases [5]. In this
review, we discuss the current understanding of the
role of NF-jB in the context of the immune response,
with relevance to a transcription factor involved in the
response to lack of oxygen (hypoxia), named hypoxia-
inducible factor (HIF). We review the crosstalk
between HIF and NF-jB in the control of the immune
response and its importance for a variety of medical
conditions.
NF-jB pathway in the immune system
NF-jB is a collective name for a family of transcrip-
tion factors composed of RelA (p65), RelB, c-Rel,
NF-jB1 (p50/p105), and NF-jB2 (p52/p100). These
subunits can be activated by many different stimuli,
including bacterial lipopolysaccharide (LPS), viral
pathogens, cytokines or growth factors [6]. This activa-
tion involves the degradation of a family of inhibitory
proteins know as IjBs. After phosphorylation of IjBs
by kinases (such as the IjB kinase (IKK) complex),
which respond to diverse stimuli, IjBs are targeted for
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degradation by the proteasome, and the NF-jB sub-
units are then liberated from the inhibitory complex
(Fig. 1A). NF-jB subunits are then able to translocate
to the nucleus to activate myriad NF-jB-specific target
genes [7,8]. NF-jB family members are capable of
forming several combinations of homo- or heterodi-
mers, in order to activate a complex regulatory net-
work that culminates with the activation or repression
of hundreds of genes [1,8–10]. Many of these genes,
such as those for cytokines, chemokines or membrane
receptors, are involved in the immune response [11–
13]. Generally, mammalian immune responses can be
grouped into innate or adaptive [14], and in both cases
the immune response starts with the recognition by the
host of the presence of unfamiliar pathogens. This
recognition triggers a chain of events that promotes
the clearance of the pathogens. Importantly, NF-jB
acts as the commander of this immunologic response
[11], although many other transcription factors are
also involved. It is through the coordination of the
several NF-jB subunits and pathways that a con-
trolled and balanced response is achieved, when cells
are stimulated by an external signal [13]. When NF-jB
is impaired or deregulated, this response is deficient or
out of control, leading to a lack of immune response,
or an excessive and damaging inflammatory response,
respectively [5,15].
NF-jB is also important for the modulation of the
proliferative balance of the immune cells. Many NF-
jB target genes, including those for Bcl-xL, inhibitors
of apoptosis protein, or granulocyte–macrophage col-
ony-stimulating factor, have been shown to regulate
the proliferative outcome of immune cells [13]. For
example, NF-jB is a key player in the control of the
proliferation or cell death of hematopoietic cells. Sev-
eral studies have shown the importance of NF-jB in
regulating processes involved in the rapid expansion of
hematopoietic cells, such as T cells, B cells, natural
killer cells and dendritic cells [16–20].
HIF pathway in the immune system
The HIF family is a master regulator of the cellular
response to low oxygen or hypoxia [21]. HIF is a het-
erodimeric transcription factor, encompassing a HIF-a
and a HIF-1b subunit. Three different HIF-a subunits
have been found (HIF-1a, HIF-2a, HIF-3a), which
have some overlapping but mostly distinct functions in
the cell [22]. Oxygen sensitivity is accomplished
through the action of a class of dioxygenase that mod-
ify the HIF-a subunits specifically. As such, prolyl
hydroxylase domain (PHD) proteins (PHD1, PHD2,
and PHD3) hydroxylate key proline residues within
the oxygen-dependent degradation domain of the HIF-
a subunits, creating a high-affinity binding site for the
E3-ligase complex containing the tumour suppressor
von Hippel–Lindau (VHL). This results in ubiquitina-
tion and proteasome-dependent degradation of HIF-a,
Fig. 1. Schematic diagram of the NF-jB and HIF activation pathways. (A) In the presence of a stimulus (such as tumour necrosis factor a,
not shown), the IKK complex is activated, and mediates the phosphorylation of IjB protein, which labels it for proteasomal degradation. This
action results in the release of the NF-jB subunits (shown as NF-jB), and translocation into the nucleus in order to activate target genes.
(B) In the presence of oxygen (normoxia) HIF-a is hydroxylated by PHD proteins (not shown), and targeted for proteasome-mediated
degradation after being polyubiquitinated by von Hippel–Lindau (VHL) protein. In the presence of low oxygen (hypoxia), HIF-a is stabilised
and interacts with the HIF-1b subunit to activate target genes containing hypoxia response elements (HRE). In normoxia, HIF can also be
stabilised by increase in its translation by mTOR, as well as through increase of its transcription by STAT3, or NF-jB.
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when oxygen is present [23]. In addition, an asparagine
hydroxylase (factor inhibiting HIF; FIH), hydroxylates
a key asparagine within the transactivation domain of
HIF-a, preventing the recruitment of coactivators
CREB binding protein (CBP) and/or p300 [24]. The
lack of association between HIF and CBP/p300 results
in reduced transcriptional activity of the complex
under normoxia or moderate hypoxia [24]. In response
to hypoxia, HIF transactivates a variety of genes
involved in many processes such as glycolysis, angio-
genesis, proliferation, migration, autophagy and
apoptosis, amongst others [21].
Although HIF is mainly associated with the hypoxia
response, the last few years have demonstrated a role
for HIF in the inflammation response. Numerous stud-
ies have shown that HIF-1a is induced in response to
infection by different pathogens and in several immune
cell types [22,25]. Similarly, recent studies have alluded
to the fact that HIF-1b and HIF-2a are also involved
in the control of the immune responses in cells, and in
model organisms, such as zebrafish and mouse [26,27].
HIF is also able to induce a number of pro-inflamma-
tory cytokines and chemokines directly, further
contributing to the inflammation response.
However, while it is possible that HIF induction fol-
lows a similar pathway to that of the hypoxia
response, additional mechanisms for HIF induction,
independent of oxygen level, have also been demon-
strated (Fig. 1B). These include, increased translation
via a mechanistic target of rapamycin (mTOR)-depen-
dent mechanism [28], but also increased transcription
in a manner dependent on either signal transducer and
activator of transcription 3 (STAT3) [29] or more com-
monly NF-jB [22]. Importantly, HIF-mediated control
of the immune responses involves an intricate crosstalk
with NF-jB.
HIF and NF-jB crosstalk
Hypoxia and inflammation have been associated with
a number of pathological conditions, in particular
inflammatory diseases [30]. As part of this complex
interaction, an extensive crosstalk between the two
main molecular players involved, HIF (hypoxia) and
NF-jB (inflammation), has been reported. This cross-
talk includes common activating stimuli, and shared
regulators and targets, as recently reviewed [31]. The
hypoxia-induced activation of the NF-jB pathway was
first reported in 1994 [32], and thereafter a number of
studies followed to elucidate the mechanisms underly-
ing this activation. For instance, hypoxia has been
identified as a common activator of both HIF and
NF-jB in an IKK–transforming growth factor
b-activated kinase 1 (TAK1)-dependent manner [33].
Also, the existence of an evolutionarily conserved neg-
ative feedback mechanism, through which HIF can
regulate NF-jB in an IKK–TAK1- and cell division
protein kinase 6 (CDK6) -dependent manner, has
emerged [34]. On the other hand, NF-jB has been
shown to be a direct modulator of HIF expression in
inflammation and hypoxia [35,36]. Despite the rela-
tively well-established ability of NF-jB to induce HIF,
the knowledge about HIF contributions to the NF-jB
pathway is still mainly limited to HIF-1a. In fact,
HIF-1a can restrict NF-jB transcriptional activity
in vivo and in vitro under inflammatory conditions
[34,37,38]. Instead, to date, only scarce attention has
been given to HIF-1b and HIF-2a subunits in the con-
text of inflammation. However, both these HIF sub-
units have been associated with NF-jB [36,39,40].
HIF and NF-jB crosstalk in the immune
system
Hypoxic response and innate and adaptive immunity
are tightly connected. The synergistic interaction
between these stress responses is mainly mediated by a
regulatory loop involving the transcription factors
HIF and NF-jB (Fig. 2). For instance, macrophages
infected with bacteria and mice subjected to hypoxia
showed a defective HIF-1a expression upon deletion
of the IKKb-encoding gene [2]. Furthermore, hypoxia
can stimulate NF-jB activation by negatively modu-
late IKKb catalytic activity through inhibition of pro-
lyl hydroxylases [41]. Several studies suggested an
Fig. 2. Schematic diagram of NF-jB and HIF roles in the immune
response. NF-jB is involved in the increase of proliferation of
several immune cells (T, B and dendritic cells). Additionally, NF-jB
and HIF share some functions in the activation of the immune
response to infection, by promoting the expression of pro-
inflammatory cytokines, and increasing the antibacterial activity.
HIF is also important for the activation of macrophages and
neutrophils (on state), as well as for the promotion of
phagocytosis.
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important role of HIF-1a in promoting the expression
of NF-jB-regulated inflammatory cytokines in macro-
phages after LPS stimulation [42], and in mediating
NF-jB activation in anoxic neutrophils [43].
Generally, while circulating in oxygen-rich blood, mye-
loid-derived phagocytes, such as neutrophils and
macrophages, maintain their bactericidal and pro-
inflammatory capacities in the ‘off-state’. Then, enter-
ing the infected tissue, in the migration across the
endothelium, they encounter a decreasing oxygen gra-
dient. In addition, the hypoxic environment character-
istic of the site of infection, resulting from an elevated
oxygen consumption by immune cells [44,45], triggers
an increased stabilisation of HIF-1a protein by reduc-
tion of prolyl hydroxylase activity. Following HIF
activation, the expression of innate immune response
genes, containing hypoxia-responsive elements in their
promoters, increases, reaching the maximal induction
through NF-jB activation after direct pathogen
encounter. This further boosts HIF-1a transcription
and enhances the host defence response. In fact, HIF
activity is involved in a series of events promoting the
‘on-state’ of the immune response, i.e. releasing pro-
inflammatory cytokines and antimicrobial peptides,
promoting phagocytosis, increasing phagocyte lifespan
by inhibiting apoptosis, and activating production of
nitric oxide (NO; which, in turn, interferes with HIF
degradation and creates an amplification loop for
phagocyte activation [46]). It has been reported that
VHL protein-lacking macrophages kill bacteria more
efficiently than wild-type macrophages thanks to
constitutive stabilisation of HIF [47]. Therefore, the
concept that HIF regulates intrinsic immunity and
inflammatory response underlies the development of
novel pharmacological approaches. For instance, the
restriction of prolyl hydroxylase access to iron, by
hypoxia-mimetic HIF-agonists, enhances murine
macrophage activity in vitro [47].
Considering the evidence that changes in oxygen
levels regulate proliferation and differentiation of mul-
tiple cell types involved in the immune system, this
review will examine the current knowledge about the
intricate crosstalk between HIF and NF-jB in neu-
trophils, macrophages, and T and B cells, culminating
in a detailed analysis of the two stress–response sys-
tems in various disease contexts.
HIF and NF-jB crosstalk in
macrophages
Macrophages are versatile hematopoietic cells that
derive from monocytes that circulate in the blood-
stream for 1–2 days before migrating into tissues and
completing their differentiation. These myeloid cells
are largely involved in the immune response, playing a
crucial role both in innate and adaptive immunity. For
instance, they initiate the inflammatory response,
phagocytose and kill bacteria, and recruit lymphocytes
[48]. Showing extensive plasticity, macrophages can
undergo two different types of activation: the classical
M1 profile, induced by interferon c or Toll-like recep-
tor (TLR) ligands, triggering a characteristic pro-
inflammatory activity; and the alternative M2 profile,
induced by specific interleukins (i.e. interleukin (IL)-4
and IL-13), typical of anti-inflammatory activity [49].
During the host response, an early event is an
increased monocyte extravasation, infiltration and
accumulation in the inflammation site. Together with
vascular damage and oedema, the intensive metabolic
activity of infiltrating cells contributes to lowering of
the oxygen tension in the inflamed tissue. Hypoxia rep-
resents an important factor affecting the human mono-
cytopoiesis [50], in particular the maturation to
macrophages. In fact, in response to decreased oxygen
levels, monocytes switch to a glycolytic metabolism
and arrest their migration induced by the chemotactic
gradient. Thus, differentiated macrophages serve as
phagocytes and accumulate in hypoxic inflammation
sites [50]. Gene expression changes, present in macro-
phages in hypoxic conditions in vitro, have been
reviewed elsewhere [51]. An example is the up-regula-
tion of molecules necessary for macrophage survival,
such as glucose transporter 1 (GLUT1) [52]. Both
HIF-1a and HIF-2a importantly regulate macrophage
functions in hypoxia, although it is still controversial
whether they have clearly distinct roles [50]. The use of
myeloid specific Hif-1a ablation in mouse models
showed that HIF-1a mediates macrophage-dependent
inflammatory and antibacterial activities [47,53]. A
recent study demonstrated that HIF-2a shares some
functions with HIF-1a, such as the regulation of acute
inflammatory response. However, this regulation does
not involve NO production or co-stimulatory molecule
expression, but promotes specific pro-inflammatory
cytokine expression, in response to M1 stimuli, and
leukocyte infiltration. Of note, in human macrophages,
HIF-2a overexpression enhanced the transcription of
proangiogenic genes (i.e. those for vascular endothelial
growth factor (VEGF), IL-8 and platelet-derived
growth factor b) even in normoxic conditions [48].
Interestingly, in human and murine macrophages,
hypoxia can activate gene expression also in a HIF-
independent manner, through the upregulation of NF-
jB, activating transcription factor 4 (ATF4), and early
growth response-1 (Egr-1) [51]. For instance, upon
hypoxia incubation, NF-jB1 (p50) has been detected
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in the nuclei of monocytes, while HIF-1a remained
cytoplasmic [54]. Also, as previously reported (see
above, HIF and NF-jB crosstalk in the immune sys-
tem), HIF and NF-jB synergistically respond against
pathogens: in fact, macrophages, infected by Gram-
negative and Gram-positive bacteria, are characterised
by a defective HIF-1a expression following ablation of
IKKb, essential regulator of NF-jB activity [2].
HIF and NF-jB crosstalk in neutrophils
Neutrophils are important myeloid cells that phagocy-
tose foreign pathogens and promote inflammation [55].
Neutrophils are short-lived and very motile cells, using
mainly glycolysis as their source of energy [55]. These
cells are attracted by cytokines to sites of infection,
and mediate the clearing of pathogen by phagocytosis
amongst other methods [55]. Several studies have
reported on the NF-jB and HIF crosstalk. Seminal
work by Walmsley and coworkers has demonstrated
that in neutrophils, HIF-1a activates NF-jB in
hypoxia to increase the survival of this type of cell
[43]. This was further confirmed using PHD3 deletion
specifically in neutrophils, leading to increased induc-
tion of HIF-1a, resulting in enhanced survival of these
cells [56]. Furthermore, HIF-1a was shown to be
required for glycolysis in neutrophils [53]. Although,
several studies have not detected HIF-2a levels in neu-
trophils, a more recent study has shown that hypoxia
and bacterial infection leads to increased HIF-2a
expression in both mouse and human neutrophils [27].
While it is clear that HIF-1a is leading to activation of
NF-jB, whether NF-jB induces HIF-1a, HIF-2a and
HIF-1b in these cells has not been formally demon-
strated. Finally, although not directly tested it is possi-
ble that HIF-1b might be required for both HIF-1a
and HIF-2a actions in these cells. However, more
research is needed in this context.
HIF and NF-jB crosstalk in T cells
Host defence to pathogen infections depends on coor-
dinated responses of various immune cell types. Partic-
ularly, T cells are lymphocytes acting as regulators and
effectors of cell-mediated immune responses. They
mature as na€ıve conventional T cells in the thymus,
and, migrating to the periphery, differentiate into sev-
eral effector subsets upon encountering certain anti-
gens or environmental conditions [57]. When T cells
are recruited from secondary lymphoid to sites of
inflammation, they are exposed to dramatic changes in
tissue signals: cytokines, chemokines, balance of nutri-
ents and oxygen available in the new microenviron-
ment can massively affect T cell metabolism and
function [58]. During development and maturation, T
cells encounter different levels of oxygen tension [59].
For instance, at the site of inflammation or in non-
lymphoid tissues, effector T cells may be exposed to
prolonged hypoxic environments, resulting in HIF-1a
protein stabilisation. Interestingly, in T lymphocytes
HIF-1a protein expression can be robustly induced
also by T cell receptor (TCR) stimulation, followed by
activation of PI3 kinase/mTOR pathway [28]. Alterna-
tively, the pro-inflammatory cytokine IL-6 drives HIF-
1a expression by activation of STAT3 transcription
factor [29]. Hypoxia can induce chemokines to selec-
tively recruit certain T cell subsets, and alter T cell
stimulation capacity by changing their antigen presen-
tation [46]. A number of studies assessed the role of
HIF-1a in VHL protein-deficient thymocytes [60] or
HIF-1a-deficient T cells. Particularly, in this context,
an increased inflammatory cell infiltration and vascular
remodelling were observed [61], suggesting HIF-1a as
a T cell negative regulator.
Interestingly, stimuli inducing HIF-1a (i.e. cytokines
and antigen stimulation) also activate NF-jB. In mur-
ine, HIF-1a-deficient T cells, an enhanced NF-jB
activity (both in p50 and RelA) was observed upon
cecal ligation [62]. The engagement of TCR, and core-
ceptor CD28, can also activate the NF-jB pathway
[63], inducing, in turn, the transcriptional activation of
a plethora of targets, such as IL-2, a cytokine involved
in T cell proliferation and survival [57]. Therefore,
NF-jB is one of the most important transcription fac-
tors contributing to T cells’ development and differen-
tiation. The majority of the studies designed to
uncover the role of NF-jB in T cell activation, expan-
sion and regulation involved genetic models of sys-
temic or conditional ablation of IKK proteins, NF-jB
subunits, and adapter components of the pathway. In
T cell development, NF-jB is involved already in the
early antigen-independent phase of thymocyte differen-
tiation, as well as the final antigen-dependent lineage
commitment and postselection maturation [20]. Fur-
ther evidence of the crosstalk between HIF and NF-jB
is that both pathways are essential in differentiation of
regulatory T cells (Tregs), by direct transcriptional
activation of Foxp3 [64,65], in which cRel and RelA/
p65 are particularly involved [20,66]. In addition, HIF-
1a also promotes the fine balance between Tregs and
the pro-inflammatory Th17 subset [29,67]. In fact, dur-
ing Th17 differentiation CD4+ T cells rely on HIF-1a
to regulate cell metabolism [67].
Moreover, a recent study reported that T cells are
more sensitive to hypoxia upon stimulation of NF-jB,
showing an enhanced HIF-1a-dependent adenosinergic
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signalling [68]. Therefore, taking into account the
numerous shared activators and targets between HIF
and NF-jB, a better understanding of their crosstalk
in T cell development and function is necessary to
specifically target the pathways in novel therapeutic
strategies.
HIF and NF-jB crosstalk in B cells
While it is clear that NF-jB is required for normal B
cell development and it is often found deregulated in B
cell malignancies [69], only recent work has demon-
strated the importance of HIF in B cells. Genetic stud-
ies using lineage-specific deletion of HIF-1a in mice
have shown that HIF-1a is required for normal B cell
development [70,71]. In fact, HIF-1a deletion resulted
in autoimmunity in chimeric mouse models [70]. How-
ever, whether HIF and NF-jB crosstalk in the cell sys-
tem has only been determined in the context of
disease. In particular, NF-jB was shown to be respon-
sible for the induction of HIF-1a mRNA in malignant
lymphoma [72]. No information is available regarding
how HIF modulates NF-jB function under these cells.
In addition, other HIF isoforms have not been investi-
gated as well. It is possible, however, that HIF-2a
might be involved in B-cell lymphomas, as a recent
study reported that HIF-2a mRNA is controlled by
E2F1 in cells, and elevated in a mouse model of B-cell
lymphoma [73]. However, much more work is needed
to fully investigate the HIF–NF-jB crosstalk in this
cell type.
HIF and NF-jB crosstalk in disease
conditions
As mentioned above there is an intimate interaction
between HIF and NF-jB, in immune cells. Impor-
tantly there are various examples of this crosstalk in
the immune response occurring in disease conditions.
These include rheumatoid arthritis (RA) [74], asthma
and chronic obstructive pulmonary disease (COPD)
[75], and cancer [76].
Crosstalk in rheumatoid arthritis
RA is a progressive autoimmune disorder caused by a
chronic inflammation of the synovium. Its characteris-
tic clinical features are pain, stiffness, swelling and
joint destruction. Normally the innate immune system
recognises microbial pathogens by action of macro-
phages and dendritic cells, triggering the production
of specific inflammatory cytokines and chemokines.
Then, innate immune system cells can travel to local
lymphoid tissues to initiate the adaptive response
when necessary. In RA the innate immune system is
pathologically continuously activated. In fact, the per-
sistent interaction among synoviocytes and innate (i.e.
macrophages, dendritic cells, etc.) or adaptive immune
cells (B and T lymphocytes) has been reported [74].
As previously described (see above, HIF and NF-jB
crosstalk in macrophages), macrophages are more
numerous at the inflamed site, because of an elevated
chemotaxis and reduced apoptosis [77]. Consequently,
macrophages are highly abundant in RA synovium.
In the RA joints, macrophages can promote inflam-
matory processes, such as lymphocyte invasion, angio-
genesis and secretion of matrix metalloproteases
(MMPs). In addition, the expanded metabolic activity
characteristic of the RA synovium contributes to
unbalancing oxygen homeostasis, enhancing hypoxia
in the microenvironment. On the other hand, hypoxia
itself is able to intensify macrophage pro-inflamma-
tory capacity by a positive regulatory loop. Confirm-
ing the pathological relevance of HIF-1a expression
by macrophages in RA synovium, HIF-1a conditional
knockout mice showed lower infiltration of myeloid
cells [53]. RA synovium is also enriched in protein of
complement system, and autocrine and paracrine-act-
ing pro-inflammatory cytokines, mainly expressed by
macrophages. Among them, TNF-a, IL-1b and IL-6,
which play an important role in the progression of
the disease and are transcriptionally upregulated by
hypoxia as well. Interestingly, TNF-a and IL-1b
expression is further induced by IL-17, produced by T
helper cells. IL-17 contributes to the inflammatory
response by induction of neutrophil recruitment and
NF-jB activation [78]. All this evidence supports the
existence of an extensive crosstalk between HIF and
NF-jB in RA, as recently reviewed [30]. A better
understanding of the molecular interaction between
the two transcription factors will be particularly rele-
vant for developing novel therapeutic strategies. The
majority of therapies currently in use are based on
TNF-a inhibitors. A treatment with recombinant
human IL-11 was shown to decrease not only the
production of TNF-a, but also NF-jB activity [79].
The same decreased TNF-a production has been
observed in macrophages upon treatment with PHD
inhibitors, in an NF-jB-dependent but HIF-1a-inde-
pendent manner [50]. A novel promising therapeutic
approach might promote the selective activation of an
M2 macrophage (anti-inflammatory) profile, consid-
ering that targeting specific macrophages would
avoid side-effects connected to a systemic depletion,
as well as allowing the reaching of remote inflamma-
tion sites.
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Crosstalk in asthma and chronic obstructive
pulmonary disease
Asthma is a chronic inflammatory disorder of airways,
in which key symptoms are wheezing, coughing, short-
ness of breath, and sputum production. Chronic
obstructive pulmonary disease (COPD) is an obstructive
lung disease characterised by narrowing of bronchioles,
limited airflow, and emphysema (irreversible of damage
to lung tissue) [75]. Supporting the fact that inflamma-
tion is a main feature of both diseases, the vast majority
of patients are currently treated by anti-inflammatory
glucocorticoids, which are, unfortunately, ineffective in
the most severe cases. Glucocorticoids target specifically
the transcription factor NF-jB [80] that, in asthma and
COPD, is activated by TNF-a, IL-1b or TLRs. In turn,
NF-jB controls the infiltration of inflammatory cells in
airways tissues, by regulating the expression of cytoki-
nes, chemokines and cell adhesion molecules [75]. Asth-
matic tissues are also characterised by mucous cell
metaplasia, as well as inflammation mediated by eosino-
philic and T helper 2 (Th2) cells [81]. Alternatively, air-
way inflammation can involve a higher number of
neutrophils, and, thus, more Th1 lymphocytes. In gen-
eral, asthmatics and individuals affected by COPD
showed higher NF-jB DNA binding, following
increased degradation of the IjB inhibitor [82,83]. In
fact, NF-jB has a pivotal role in the regulation of
inflammatory gene expression in airway cells. For
instance, it regulates IL-2 and IL-4 production, respec-
tively in Th1 and Th2 cells. Also, it controls IL-8 expres-
sion both in neutrophils and macrophages [75]. A deep
understanding of the NF-jB-mediated regulatory mech-
anism associated with neutrophilic response in asthma
and COPD patients is relevant to overcoming the related
steroid resistance. To date, several efforts have been
made in the targeting of NF-jB pathway intermediates
in an experimental mouse model of asthma and COPD
[75]. However, this field of research needs further inves-
tigations, especially considering a possible crosstalk with
hypoxia. The role of HIF in asthma is still controversial,
and in most cases associated specifically with allergic
asthma. Upregulation of HIF-1a and HIF-2a occurs in
mouse model of allergic airway inflammation together
with an increase in eosinophil recruitment and VEGF
expression [84]. These few preliminary results open new
possibilities of asthma treatment by using inhibitors of
HIF; however, additional research is needed.
Crosstalk in cancer
Recent findings firmly establish that HIF is involved in
tumourigenesis, interacting with a variety of other tran-
scription factors, such as STAT3, Myc, Notch, and
NF-jB [76]. Particularly, increased expression of HIF-
1a has been associated with metastasis and poor prog-
nosis in a number of cancer subtypes. Neoplastic areas
show a high level of hypoxia, producing, in turn, pro-
inflammatory mediators responsible for the recruitment
of more immune cells at tumour sites. Frequently, this
results in chronic inflammation, with a relevant activa-
tion of NF-jB. Several reports support a collaboration
between HIF and NF-jB in tumourigenesis promotion,
through activation of genes (i.e. genes for IL-6,
cyclooxygenase 2, MMP-9, etc.), as well as in induction
of prosurvival genes, such as that for Bcl-2 [76]. In
addition, HIF-1a controls the tumour-associated
inflammatory response mediating activation of TLR4.
A classic example of cancer characterised by chronic
inflammation is the hepatocellular carcinoma (HCC)
[85]. A key feature of this cancer type is the constant
expression of cytokines recruiting immune cells to the
liver. In this context, an important role is played by
TNF-a, activated directly by NF-jB, and by tumour-
associated macrophages (TAMs). They are the main
component of leukocyte infiltration, and, due to their
plasticity, TAMs own both pro- and anti-inflammatory
properties. For example, inhibition of TNF-a resulted
in a reduction of HCC cells, attributing a protumoural
function to NF-jB activation in macrophages [86].
According to this, TAMs isolated from NF-jB1–/– mice
showed a preferred activation of antitumoural M1
expression profile [87]. However, evidence about the
role of TAMs is still controversial, and further clarifica-
tion is needed, taking into consideration that TAMs
apparently accumulate in scarcely vascularised and
hypoxic regions. Expression of HIF-1a and HIF-2a in
TAMs seems to be involved in HCC progression with
overlapping functions [48,88]. Therefore, macrophages
are currently considered a possible effective vehicle to
target hypoxia-regulated genes in solid tumours, other-
wise not accessible to classic therapeutic agents circulat-
ing in the bloodstream.
Potential for new therapeutic approaches
targeting the HIF-NF-jB crosstalk
Given the crosstalk described above, it is plausible to
think that targeting the HIF pathway will impact on
NF-jB function. In fact, a number of studies using
both genetic and chemical inhibition of the PHD pro-
teins have demonstrated therapeutic effects in disease
models such as colitis and even in response to infection
[89,90], where inflammation and NF-jB play an
important role. It would therefore be interesting to
expand the possible therapeutic effect of both HIF
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activators and inhibitors to other diseases of the
immune system such as RA and COPD. However, tar-
geting of the individual HIF-a isoforms might be
required to achieve the desired therapeutic effects.
Additional work, using the available HIF modulators
in these disease models, is necessary to test the efficacy
of these drugs in different settings, and such work
could be very informative in the understanding of
what form HIF–NF-jB crosstalk takes in diverse cell
types.
Summary
An intricate and complex crosstalk between HIF and
NF-jB exist in many cell types (Fig. 3). The ultimate
outcome is very much cell type dependent. While in
certain cell types, these transcription factors cooperate,
which is evident in the case of neutrophils, in other
cells, they antagonise each other such as in subtypes of
T cells (Fig. 3). This, however, presents an opportunity
for specialised clinical intervention, as several HIF
agonists that could be used for immune-related dis-
eases are in clinical development.
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